Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
NCT04085029
This study is recruiting at 5 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Oligometastasis
- Metastatic Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Duke University
- Last updated on ClinicalTrials.gov
- February 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 5
- Duke Cancer Institute Cary · Cary, NC
- Duke University Medical Center · Durham, NC
- Durham Veterans Administration Health Care System (DVAHCS) · Durham, NC
- Duke Raleigh Hospital · Raleigh, NC
- Duke Women's Cancer Care Raleigh · Raleigh, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.